TBPH
TBPH clinical trials: Theravance Biopharma, Inc.
Every trial on ClinicalTrials.gov where Theravance Biopharma, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 75
- Trials linked
- 47
- As lead sponsor
- 28
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
TBPH on the catalyst calendar · TBPH registry changes
- Primary completion Jan 2026Sponsor estimatePhase 3NCT05696717Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System AtrophyTheravance Biopharma · Symptomatic Neurogenic Orthostatic HypotensionActive, not recruitingTBPHLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 13, 2023ActualPhase 4NCT05165485Phase 4 COPD and Suboptimal Inspiratory Flow RateTheravance Biopharma · Chronic Obstructive Pulmonary DiseaseCompletedTBPHLeadVTRSCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 30, 2021ActualPhase 2NCT03635112Efficacy and Safety of TD-1473 in Crohn's DiseaseTheravance Biopharma · Crohn's DiseaseTerminatedTBPHLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 10, 2021ActualPhase 3NCT03829657Phase 3 Clinical Effect Durability of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic FailureTheravance Biopharma · Symptomatic Neurogenic Orthostatic HypotensionTerminatedTBPHLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 12, 2021ActualPhase 3NCT04095793Phase 3 Open-Label Extension Study of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic FailureTheravance Biopharma · Symptomatic Neurogenic Orthostatic HypotensionTerminatedTBPHLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 20, 2021ActualPhase 2/Phase 3NCT03758443Efficacy & Safety of TD-1473 in Ulcerative ColitisTheravance Biopharma · Ulcerative Colitis (UC)TerminatedTBPHLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 27, 2021ActualPhase 2/Phase 3NCT03920254TD-1473 Long-Term Safety (LTS) Ulcerative Colitis (UC) StudyTheravance Biopharma · Ulcerative Colitis (UC)TerminatedTBPHLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 24, 2018ActualPhase 2NCT02705755TD-9855 Phase 2 in Neurogenic Orthostatic Hypotension (nOH)Theravance Biopharma · Neurogenic Orthostatic HypotensionCompletedTBPHLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 21, 2021ActualPhase 3NCT03750552Clinical Effect of Ampreloxetine (TD-9855) for Treating Symptomatic nOH in Subjects With Primary Autonomic FailureTheravance Biopharma · Symptomatic Neurogenic Orthostatic HypotensionCompletedTBPHLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 2013ActualPhase 2NCT01458340A Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)Theravance Biopharma · Attention-Deficit/Hyperactivity DisorderCompletedTBPHLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 21, 2021ActualPhase 2NCT04402866TD-0903 for ALI Associated With COVID-19Theravance Biopharma · Acute Lung Injury (ALI) Associated With COVID-19CompletedTBPHLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 28, 2020ActualPhase 2NCT04150341Effect of Inhaled TD-8236 on Allergen-induced Asthmatic ResponseTheravance Biopharma · AsthmaCompletedTBPHLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2014ActualPhase 2NCT01693692Phase 2 Study of TD-9855 to Treat FibromyalgiaTheravance Biopharma · FibromyalgiaCompletedTBPHLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 6, 2021ActualPhase 1NCT04589260TD-1058 First-In-Human Study in Healthy Subjects and Subjects With Idiopathic Pulmonary FibrosisTheravance Biopharma · Idiopathic Pulmonary Fibrosis (IPF)TerminatedTBPHLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 22, 2021ActualNo phase registeredNCT04681079Comparison of Viral Particle Dispersion Following Administration of an MDI or Nebulizer in Subjects With COVID-19Theravance Biopharma · COVID-19CompletedTBPHLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 24, 2021ActualPhase 1NCT05091723TD-0903 Pharmacokinetics Study in Healthy Participants With Supplemental OxygenationTheravance Biopharma · Acute Lung Injury (ALI) Due to Coronavirus Disease-2019 (COVID-19)CompletedTBPHLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 2016ActualPhase 1NCT02639078Single Ascending Dose Study of TD-0714 in Healthy SubjectsTheravance Biopharma · HealthyCompletedTBPHLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 13, 2020ActualPhase 1NCT03652038Single and Multiple Ascending Dose Study of TD-8236 by InhalationTheravance Biopharma · AsthmaCompletedTBPHLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 29, 2018ActualPhase 1NCT02818686TD-1473 for Active Ulcerative Colitis (UC)Theravance Biopharma · Ulcerative Colitis, Active ModerateCompletedTBPHLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 17, 2016ActualPhase 1NCT02663089A Phase 1 (Ph1), Single Dose (SD), GSK961081 Absorption, Distribution, Metabolism, and Excretion (ADME) Study in Healthy SubjectsTheravance Biopharma · Pulmonary Disease, Chronic ObstructiveCompletedTBPHLeadGSKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 4, 2006ActualPhase 1NCT00887406Study of GSK961081 in Healthy Volunteer SubjectsTheravance Biopharma · Pulmonary Disease, Chronic ObstructiveCompletedTBPHLeadGSKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 27, 2008ActualPhase 1NCT00687700A Study to Investigate the Pharmacology of a Dual Pharmacophore in Healthy VolunteersTheravance Biopharma · Pulmonary Disease, Chronic ObstructiveCompletedTBPHLeadGSKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 1, 2008ActualPhase 2NCT00674817An Investigation Of The Interaction Of GSK961081 With Inhaled Beta-Agonist And Anti-Muscarinic Drugs.Theravance Biopharma · Pulmonary Disease, Chronic ObstructiveCompletedTBPHLeadGSKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 8, 2008ActualPhase 1NCT00550225Succinate Salt Version of GSK961081 for Healthy VolunteersTheravance Biopharma · Pulmonary Disease, Chronic ObstructiveCompletedTBPHLeadGSKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 19, 2021ActualPhase 1NCT04200573Effect of Hepatic Impairment on the Pharmacokinetics of a Single Dose of TD-9855Theravance Biopharma · Symptomatic Neurogenic Orthostatic HypertensionCompletedTBPHLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 50 more in this window; the full list is part of TrialScanner.
Unlock with TrialScanner